TEI 3356

a prostaglandin E receptor agonist; inhibits endothelin-induced DNA synthesis in cultured vascular smooth muscle cells; structure given in first source

Also Known As:

5-(-7-hydroxy-6-(4-hydroxy-4-methyl-1-octenyl)bicyclo(3.3.0)oct-2-en-3-yl)pentanoic acid; TEI-3356; 2-Pentalenepentanoic acid, 1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(4-hydroxy-4-methyl-1-octenyl)-, (3aS-(3aalpha,5beta,6alpha(1E,4R*),6aalpha))-

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Infarction (Infarctions) 02/12/1999 - "TEI-3356 (1 microg/kg/min i.v., n = 6) caused a significant reduction in infarct size from 60+/-3% (control, n = 8) to 38+/-3% of the area at risk. " 02/12/1999 - "The reduction in infarct size afforded by TEI-3356 was also abolished by the protein kinase C inhibitors staurosporine (1 microg/kg i.v., n = 6) and chelerythrine (0.7 mg/kg i.v., n = 5). " 02/12/1999 - "The effects of the prostanoid EP3 receptor agonist TEI-3356 on either protein kinase C or ATP-sensitive (K(ATP)) K+ channels and on the infarct size caused by regional myocardial ischaemia and reperfusion in the rat were investigated. "
2.	Myocardial Infarction 02/12/1999 - "Thus, TEI-3356 reduces myocardial infarct size in the rat by a mechanism(s) which involves the activation of protein kinase C and the opening of K(ATP)-channels."

Related Drugs and Biologics

1.	Staurosporine
2.	Protein Kinase C
3.	Prostaglandins
4.	Adenosine Triphosphate (ATP)
5.	chelerythrine